 |
|
|
| |
Sofosbuvir/velpatasvir compared to existing Standards of Care in GT2-6 HCV
Real-world experience from the TRIO Network
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Michael Curry1, Bruce Bacon2, Douglas T. Dieterich3, Steven L. Flamm4, Kris Kowdley5, Scott Milligan6, Naoky Tsai7, Zobair Younossi8 and Nezam Afdhal1
1Beth Israel Deaconess Medical Center, 2Saint Louis University School of Medicine, 3Icahn School of Medicine at Mount Sinai, 4Northwestern University Feinberg School of Medicine, 5Liver Care Network, Swedish Medical Center, 6Trio Health Analytics, 7Queens Medical Center, University of Hawaii, and 8Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital
Reported by Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Michael Curry1, Bruce Bacon2, Douglas T. Dieterich3, Steven L. Flamm4, Kris Kowdley5, Scott Milligan6, Naoky Tsai7, Zobair Younossi8 and Nezam Afdhal1
1Beth Israel Deaconess Medical Center, 2Saint Louis University School of Medicine, 3Icahn School of Medicine at Mount Sinai, 4Northwestern University Feinberg School of Medicine, 5Liver Care Network, Swedish Medical Center, 6Trio Health Analytics, 7Queens Medical Center, University of Hawaii, and 8Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital
|
| |
|
|
|
|
|
